checkAd

DGAP-Adhoc Carl Zeiss Meditec AG returns to significant revenue growth in second quarter 2020/21

Nachrichtenquelle: EQS Group AG
19.04.2021, 10:06  |  136   |   |   

DGAP-Ad-hoc: Carl Zeiss Meditec AG / Key word(s): Half Year Results
Carl Zeiss Meditec AG returns to significant revenue growth in second quarter 2020/21

19-Apr-2021 / 10:06 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Handeln Sie Ihre Einschätzung zu Carl Zeiss Meditec AG!
Long
Basispreis 130,59€
Hebel 9,45
Ask 1,54
Short
Basispreis 163,06€
Hebel 7,62
Ask 1,91

Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.


Carl Zeiss Meditec AG returns to significant revenue growth in second quarter 2020/21

Jena, April 19, 2021

Carl Zeiss Meditec AG (ISIN: DE0005313704) has achieved revenue of EUR 767.4 million in the first half of fiscal year 2020/21 (previous year: EUR 714.9 million). This corresponds to a revenue development of +7.3% vs. the past year (after adjustment for currency effects[1]: +10.5%). In the second quarter of FY 2020/21, revenue amounted to EUR 398.5 million (past year: EUR 345.3 million) - a growth rate of +15.4% (after adjustment for currency effects: +18.8%).

Earnings before interest and taxes (EBIT)[2] amounted to EUR 162.7 million in the first half of FY 2020/21 (past year: EUR 102.5 million). EBIT margin (EBIT / revenue) was 21.2% (past year 14.3%). In the second quarter of FY 2020/21, EBIT amounted to EUR 89.3 million (past year: EUR 45.7 million). EBIT margin was 22.4% (past year: 13.2%). EBIT benefitted in part from a favorable development of product mix as well as a continuing low level of sales and marketing expenses due to the COVID-19 pandemic, compared to the past year.

Earnings per share (EPS)[3] amounted to EUR 1.12 (past year: EUR 0.71) for the first half of FY 2020/21. In the second quarter, EPS amounted to EUR 0.60 (past year: EUR 0.28).

Full results for the first half 2020/21 will be published on May 10, 2021.

During the further course of FY 2020/21, the company expects an ongoing normalization of business development. This expectation is based on the assumption that there will be no renewed deterioration in the global pandemic situation.
Seite 1 von 3
Carl Zeiss Meditec Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de






0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

DGAP-Adhoc Carl Zeiss Meditec AG returns to significant revenue growth in second quarter 2020/21 DGAP-Ad-hoc: Carl Zeiss Meditec AG / Key word(s): Half Year Results Carl Zeiss Meditec AG returns to significant revenue growth in second quarter 2020/21 19-Apr-2021 / 10:06 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the …

Community

Nachrichten des Autors

Titel
Titel
Titel